Information for the treatment of Immune Thrombocytopenia for Paediatrics



Eltrombopag

Second Line Treatment

Eltrombopag is a Thrombopoietin Receptor Agonist (TPO-RA).

Eltrombopag is a medicine used to treat children with low blood platelet counts due to persistent or chronic immune thrombocytopenia (ITP) when other treatments or surgery to remove the spleen have not worked well enough. It is used to try to raise platelet counts to lower your risk of bleeding. It is not used to make platelet counts normal.



BRAND NAMES Revolade



HOW DOES THE TREATMENT WORK?

Revolade stimulates the bone marrow to produce more platelets. It binds to the thrombopoietin receptor on megakaryocytes, which stimulates platelet production.



HOW IS IT ADMINISTERED?

Oral tablet or suspension taken daily.



DOSAGE

The usual starting dose for paediatric ITP patients 1 to 5 years of age is one 25mg eltrombopag tablet daily.

The usual starting dose for paediatric ITP patients 6 to 17 years of age is one 50mg eltrombopag tablet daily.



COMMON SIDE EFFECTS

Sore throat, runny nose, nasal congestion and sneezing, infection in the nose, sinuses, throat and upper airways, common cold (upper respiratory tract), cough, abdominal pain and fever.



RARE SIDE EFFECTS

High platelet counts and higher risk for blood clots. Platelet count may drop suddenly if the drug is stopped abruptly. Increases the risk for serious liver problems.



TREATMENT RESPONSE

1-3 weeks

Information for the treatment of Immune Thrombocytopenia for Paediatrics



Eltrombopag

Second Line Treatment



LIKELIHOOD OF AN INITIAL RESPONSE

Approximately 60-90% of patients have an initial response of a platelet count greater than 50×10^{9} L.



LIKELIHOOD OF A LONG-TERM RESPONSE?

Approximately 80% of patients who respond initially maintain a platelet count of about $50 \times 10^9 \text{L}$ if treatment is continued. The prevalence of sustained remission off treatment has yet to be established.



OTHER CONSIDERATIONS

- Take eltrombopag at least 2 hours before food AND 4 hours after food.
- Other products that may impact this treatment include antacids, multivitamins, mineral supplements, foods or products that contain iron, calcium, aluminium, magnesium, selenium, and zinc.
- Weekly blood tests until a dose of eltrombopag is established to keep your platelet count levels stable, and then you can proceed to monthly blood tests or even less frequently.
- Regular monthly monitoring of liver enzymes is recommended.
- For some, taking eltrombopag may lead to a treatment-free response.
- Eltrombopag is currently available for chronic ITP patients.

REFERENCES

https://itpaustralia.org.au/itp-in-children/

https://ashpublications.org/blood/article/142/Supplement%201/1223/502377/A-Phase-3-Study-of-Eltrombopag-Vs-Standard-First http://itpaustralia.org.au/wp-content/uploads/2024/10/2023-ANZCHOG-Paediatric-ITP-Treatment-Guidelines.pdf

This information is for information purposes only. It is not intended to substitute professional medical advice and should not be solely relied on as health or personal advice. Always seek the guidance of your healthcare professional with any questions you may have regarding your health or specific treatments. OCT24